Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of pericardial effusion and mitral and tricuspid regurgitation. He remained in remission 3 years after therapy.
Onitilo
Adedayo A
AA
Department of Hematology/Oncology, Marshfield Clinic-Wausau Center, Wausau, WI 54449, USA. onitilo.adedayo@marshfieldclinic.org
Kio
Ebenezer A
EA
Singh
Avtar K
AK
Lazarchick
John
J
D001022:Aortic Valve Insufficiency; D001549:Benzamides; D006332:Cardiomegaly; D002898:Chromosomes, Human, Pair 8; D020732:Cytogenetic Analysis; D006331:Heart Diseases; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008875:Middle Aged; D008944:Mitral Valve Insufficiency; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D014314:Trisomy
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate